Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
Authors:
- Walter P. MaksymowychWMWalter P. Maksymowych
- Stanley J. NaidesSNStanley J. Naides
- Vivian BykerkVBVivian Bykerk
- Katherine A. SiminovitchKSKatherine A. Siminovitch
- Dirkjan van SchaardenburgDSDirkjan van Schaardenburg
- Maarten BoersMBMaarten Boers
- Robert LandewéRLRobert Landewé
- Désirée van der HeijdeDHDésirée van der Heijde
- Paul-P. TakPTPaul-P. Tak
- Mark C. GenoveseMGMark C. Genovese
- Michael E. WeinblattMWMichael E. Weinblatt
- Edward C. KeystoneEKEdward C. Keystone
Open Access
- 15 August 2014
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 41 (11) , 2104-2113
Abstract
Objective.: Serum 14-3-3η is a novel joint-derived proinflammatory mediator implicated in the pathogenesis of rheumatoid arthritis (RA). In our study, we assessed the diagnostic utility of 14-3-3η and its association with standard clinical and serological measures.Methods.: A quantitative ELISA was used to assess 14-3-3η levels. Early (n = 99) and established patients with RA (n = 135) were compared to all controls (n = 385), including healthy subjects (n = 189). The sensitivity, specificity, positive and negative predictive values of 14-3-3η, and the likelihood ratios (LR) for RA were determined through receiver-operator curve analysis. The incremental value of adding 14-3-3η to anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in diagnosing early and established RA was assessed.Results.: Serum 14-3-3η differentiated established patients with RA from healthy individuals and all controls (p < 0.0001). A serum 14-3-3η cutoff of ≥ 0.19 ng/ml delivered a sensitivity and specificity of 77% and 93%, respectively, with corresponding LR positivity of 10.4. At this cutoff in early RA, 64% of patients with early RA were positive for 14-3-3η, with a corresponding specificity of 93% (LR+ of 8.6), while 59% and 57% were positive for ACPA or RF, respectively. When ACPA, RF, and 14-3-3η positivity were used in combination, 77 of the 99 patients (78%) with early RA were positive for any 1 of the 3 markers. Serum 14-3-3η did not correlate with C-reactive protein, erythrocyte sedimentation rate, or Disease Activity Score, but patients who were 14-3-3η-positive had significantly worse disease.Conclusion.: Serum 14-3-3η is a novel RA mechanistic marker that is highly specific, associated with worse disease, and complements current markers, enabling a more accurate diagnosis of RA.Keywords
This publication has 16 references indexed in Scilit:
- 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damageArthritis Research & Therapy, 2014
- Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritisArthritis Research & Therapy, 2012
- Should Anti-citrullinated Protein Antibody and Rheumatoid Factor Status Be Reassessed During the First Year of Followup in Recent-Onset Arthritis? A Longitudinal StudyThe Journal of Rheumatology, 2011
- Implementation of a treat-to-target strategy in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort studyArthritis & Rheumatism, 2011
- Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?Rheumatology, 2010
- Regulation of Protein Citrullination through p53/PADI4 Network in DNA Damage ResponseCancer Research, 2009
- Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytesJournal of Cellular Physiology, 2009
- Membrane vesicles as conveyors of immune responsesNature Reviews Immunology, 2009
- Overview of work disability in rheumatoid arthritis patients as observed in cross‐sectional and longitudinal surveysArthritis Care & Research, 2004
- Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS)Annals of the Rheumatic Diseases, 2002